Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(10): 597-601
DOI: 10.1055/s-0034-1382034
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Evaluation of Drug Interaction of Glimepiride with Phosphodiesterase Inhibitors Type V in Diabetic Nephropathy

A. S. Tripathi
1   Department of Pharmacology, P. Wadhwani College of Pharmacy, Yavatmal, Maharashtra, India
,
P. M. Mazumder
2   Department of Pharmaceutical Sciences, Birla Institute of Technology, Mesra, Ranchi, Jharkhand, India
,
A. V. Chandewar
3   Department of Pharmaceutical Chemistry, P. Wadhwani College of Pharmacy, Yavatmal, Maharashtra, India
› Author Affiliations
Further Information

Publication History

received 24 January 2014
first decision 02 May 2014

accepted 28 May 2014

Publication Date:
08 July 2014 (online)

Also available at
    Permissions and Reprints

Abstract

The present study investigate the drug interaction of Glimepiride (GLIM) with Sildenafil Citrate (SIL) in Diabetic Nephropathy (DN) rats. Diabetes was induced in rats by administering Streptozotacin i. e. STZ (60 mg/kg). In present investigation GLIM (0.5 mg/kg, P.O.) and SIL (2.5 mg/kg, P.O.) were given for 6 weeks after the confirmation of DN. Pharmacodynamic and kinetic parameters were estimated after 1st dose and at the end of 6th week of drug administration. There was significant (p<0.001) increase in the bioavailability of GLIM in the presence of SIL in DN after the 1st dose of administration of the drug as compared to GLIM treated rat, whereas at the end of 6th week of drug administration, there were significant (p<0.0001) decrease in the bioavailability of GLIM+SIL treated DN rats compared to GLIM treated rats. There was significant (P<0.01) reduction of blood glucose level in GLIM+SIL treated group as compare to only GLIM treated group on 1st dose of drug administration but after continuous treatment for next 6 weeks, GLIM treated group showed significant hypoglycemia which was found to be reduced in GLIM+SIL treated group significantly. The present study concluded that GLIM+SIL treatment reduces the hypoglycemic condition which was there for GLIM treated DN rat.

Key words

diabetic nephropathy - glimepiride - sildenafil citrate - drug interaction
 

  • References

  • 1 United States Renal Data System . USRDS Annual Data Report. Bethesda, MD: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services; 2007
    Google Scholar
  • 2 Dominique LM, Ephi B, Hannah L et al. Relationship of Depression to Diabetes Types 1 and 2: Epidemiology. Biology, and Treatment Biological Psychiatry 2003; 54: 317-329
    PubMedGoogle Scholar
  • 3 National Institute of Diabetes and Digestive and Kidney Diseases. National Diabetes Statistics 2007
    PubMed
  • 4 Giancarlo V. Thiazolidinediones – Benefits on microvascular complications of type 2 diabetes. Journal of Diabetes and Its Complications 2005; 19: 168-177
    CrossrefPubMedGoogle Scholar
  • 5 Xiaoyan X, Bin M. Cellular and humonal immune responses in the early stage of diabetic nephropathy. Journal of autoimmnity 2009; 32: 85-93
    PubMedGoogle Scholar
  • 6 Peters V, Schmitt CP. Murine models of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2012; 120: 191-193
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Yoshihiro K, Masayuki I, Takanori S et al. Sildenafil, a phosphodiesterase type 5 inhibitor, attenuates diabetic nephropathy in non-insulin-dependent Otsuka Long-Evans Tokushima Fatty rats. British Journal of Pharmacology 2011; 162: 1389-1400
    CrossrefPubMedGoogle Scholar
  • 8 Galiè N, Ghofrani HA, Torbicki A et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157
    CrossrefPubMedGoogle Scholar
  • 9 Gylfe E, Hellman B, Sehlin J et al. Interaction of sulfonylurea with the pancreatic B-cell. Experientia 1984; 40: 1126
    CrossrefPubMedGoogle Scholar
  • 10 Vardi M, Nini A. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus. Cochrane Database Syst Rev 2007; 1 CD002187
    PubMedGoogle Scholar
  • 11 Kloner RA. Novel phosphodiesterase type 5 inhibitors: Assessing hemodynamic effects and safety parameters. Clin Card 2004; 27: 120-125
    PubMedGoogle Scholar
  • 12 Wilkens H, Guth A, Konig J et al. Effect of inhaled iloprost oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222
    CrossrefPubMedGoogle Scholar
  • 13 Ghofrani H, Reichenberg F, Kohsta MG et al. Sildenafil increased excercise capacity capacity during hypoxia at low altitude and at Mount Everest. Ann Intern Med 2004; 141: 169-177
    CrossrefPubMedGoogle Scholar
  • 14 Vallance P, Leone A, Calver A et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575
    CrossrefPubMedGoogle Scholar
  • 15 Griffi K, Picken M, Bidani A. Radiotelemetric BP monitoring, antihypertensives and glomeruloprotection in remnant kidney model. Kidney Int 1994; 46: 1010-1018
    CrossrefPubMedGoogle Scholar
  • 16 Bidani AK, Griffin KA, Bakris G et al. Lack of evidence of pressure-independent protection by renin-angiotensin system blockade after renal ablation. Kidney Int 2000; 57: 1651-1661
    CrossrefPubMedGoogle Scholar
  • 17 Bernardo R, Atilio F, Valentina V, Yasmir Q et al. Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney International 2005; 68: 2131-2142
    CrossrefPubMedGoogle Scholar
  • 18 Kakadiya J, Shah M, Shah N. Glimepiride reduces on experimentally induced ischemia/reperfusion in diabetic rats. International Journal of Applied Biology and Pharmaceutical Technology 2010; I 15-19
    PubMedGoogle Scholar
  • 19 Tesch GH, Allen TJ. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology 2007; 12: 261-266
    CrossrefPubMedGoogle Scholar
  • 20 Tripathi AS, Sheikh I, Dewani AP et al. Development and validation of RP-HPLC method for sildenafil citrate in rat plasma-application to pharmacokinetic studies. Saudi Pharmaceutical Journal 2012; 21: 317-321a
    PubMedGoogle Scholar
  • 21 Tripathi AS, Dewani AP, Shelke PG et al. Development and validation of RP-HPLC method for simultaneous estimation of glimepiride and sildenafil citrate in rat plasma-application to pharmacokinetic studies. Drug Res (Stuttg) 2013; 63: 510-514b
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Bando K, Yamada Y. Glimepiride (Amaryl): a review of its pharmacological and clinical profile. Nippon Yakurigaku Zasshi 2000; 118: 59-67
    PubMedGoogle Scholar
  • 23 Sato J, Ohsawa I, Oshida Y et al. Effects of glimepiride on in vivo insulin action in normal and diabetic rats. Diabetes Res Clin Pract 1993; 22: 3-9
    CrossrefPubMedGoogle Scholar
  • 24 Abrass CK. Cellular lipid metabolism and the role of lipids in progressive renal disease. Am J Nephrol 2004; 24: 46-53
    CrossrefPubMedGoogle Scholar
  • 25 Vaziri ND, Liang K, Park JS. Acquired lecithin: Cholesterol acyltransferase (LCAT) deficiency in nephrotic syndrome. Am J Physiol 2001; 49: F823-F829
    PubMedGoogle Scholar
  • 26 Cohen MP, Ziyadeh FN, Chen S. Amadori-modified glycated serum proteins and accelerated atherosclerosis in diabetes: pathogenic and therapeutic implications. J Lab Clin Med 2006; 147: 211-219
    CrossrefPubMedGoogle Scholar
  • 27 Day JF, Thorpe SR, Baynes JW. Nonenzymatically glucosylated albumin: in vitro preparation and isolation from normal human serum. J Biol Chem 1979; 254: 595-597
    PubMedGoogle Scholar
  • 28 Ruiz-Cabello F, Erill S. Abnormal serum protein binding of acidic drugs in diabetes mellitus. Clin Pharmacol Ther 1984; 36: 691-695
    CrossrefPubMedGoogle Scholar
  • 29 Worner W, Preissner A, Rietbrock N. Drug-protein binding kinetics in patients with type I diabetes. Eur J Clin Pharmacol 1992; 43: 97-100
    CrossrefPubMedGoogle Scholar
  • 30 Kearns GL, Kemp SF, Turley CP et al. Protein binding of phenytoin and lidocaine in pediatric patients with type I diabetes mellitus. Dev Pharmacol Ther 1988; 11: 14-23
    PubMedGoogle Scholar
  • 31 Kemp SF, Kearns GL, Turley CP. Alteration of phenytoin binding by glycosylation of albumin in IDDM. Diabetes 1987; 36: 505-509
    CrossrefPubMedGoogle Scholar
  • 32 Trovik TS, Jaeger R, Jorde R et al. Plasma protein binding of catecholamines, prazosin and propranolol in diabetes mellitus. Eur J Clin Pharmacol 1992; 43: 265-268
    CrossrefPubMedGoogle Scholar
  • 33 Trovik TS, Jaeger R, Jorde R et al. Reduced sensitivity to beta-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness. Br J Clin Pharmacol 1994; 38: 427-432
    CrossrefPubMedGoogle Scholar
  • 34 Reidenberg MM, Drayer DE. Alteration of drug-protein binding in renal disease. Clin Pharmacokinet 1984; 9: 18-26
    CrossrefPubMedGoogle Scholar
  • 35 Keller F, Maiga M, Neumayer HH et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 1984; 9: 275-282
    CrossrefPubMedGoogle Scholar
  • 36 Gatti G, Crema F, Attardo-Parrinello G et al. Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 1987; 9: 389-391
    CrossrefPubMedGoogle Scholar
  • 37 McNamara PJ, Blouin RA, Brazzell RK. The protein binding of phenytoin, propranolol, diazepam, and AL01576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 1988; 5: 261-265
    CrossrefPubMedGoogle Scholar
  • 38 Zini R, Riant P, Barre J et al. Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (part II). Clin Pharmacokinet 1990; 19: 218-229
    CrossrefPubMedGoogle Scholar
  • 39 Zini R, Riant P, Barre J et al. Disease-induced variations in plasma protein levels: implications for drug dosage regimens part (part I). Clin Pharmacokinet 1990; 19: 147-159
    CrossrefPubMedGoogle Scholar
  • 40 Okabe N, Hashizume N. Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism. Biol Pharm Bull 1994; 17: 16-21
    CrossrefPubMedGoogle Scholar
  • 41 Thomas S. Diabetic nephropathy. Medicine 2010; 38: 639-643
    CrossrefPubMedGoogle Scholar
  • 42 Vaziri ND. Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension. Curr Opin Nephrol Hypertens 2004; 13: 93-99
    CrossrefPubMedGoogle Scholar
  • 43 Himmelfarb J, Stenvinkel P, Ikizler TA et al. The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002; 62: 1524-1538
    CrossrefPubMedGoogle Scholar
  • 44 Das A, Xi L, Kukreja RC. Phosphodiesterase-inhibitor, sildenafil preconditions adult cardiac myocytes agains necrosis and apoptosis: Essential role of NO signaling. J Biol Chem 2005; 280: 12944-12955
    CrossrefPubMedGoogle Scholar
  • 45 Chao J, Chao L. Kallikrein-kinin in stroke, cardiovascular and renal disease. Exp Physiol 2005; 90: 291-298
    CrossrefPubMedGoogle Scholar
  • 46 Valente EG, Vernet D, Ferrini MG et al. L-arginine and hosphodiesterase (PDE) inhibitors counteract fibrosis in Peyronie’s fifrotic plaque and related fibroblast cultures. Nitric Oxide 2003; 9: 229-244
    CrossrefPubMedGoogle Scholar